A leading RNAi therapeutics company.

Today’s anti-viral medications are limited within their mechanism of action and by emergence of resistant flu strains, stated Benjamin tenOever, Ph.D., Associate Professor, Microbiology of The Mount Sinai INFIRMARY. Our lab’s curiosity in the biology of flu infection has resulted in the discovery of svRNAs that may actually control the change from viral genome transcription toward viral replication. We are excited to utilize Alnylam on RNA therapeutics targeting svRNAs as a new approach for anti-viral medications. Related StoriesDengue-infected individuals with few or no symptoms transmit virus to mosquitoesBlocking calcium-signaling pathway could inhibit Ebola virus and other sources of deadly infectionsJohns Hopkins doctors desire people to get vaccinated against influenza virusThe brand-new study describes the discovery of influenza A svRNAs and their role as part of a viral mechanism to regulate the switch between transcription and replication, representing a fresh paradigm in virus biology.By contrast, affective psychosis was slightly more prevalent in women than men and there was less variation with age group. All privileges reserved. Neither of the parties endorse or recommend any commercial products, services, or equipment.. Active Biotech, Teva to commence third Phase III research of laquinimod for RRMS Teva Pharmaceutical Sectors Ltd. and Active Biotech provided today an update on the clinical development plan of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis . The companies are to initiate a third Phase III research of laquinimod, following a written contract reached with the U.S. Food and Drug Administration on the Special Protocol Assessment .6mg and 1.2mg) in approximately 1,800 patients for to 24 months up. The primary end result measure will be verified disability progression as measured by the Expanded Disability Status Scale .